RENOVORX INC (RNXT) Stock Price & Overview
NASDAQ:RNXT • US75989R1077
Current stock price
The current stock price of RNXT is 1.03 USD. Today RNXT is up by 0.98%. In the past month the price increased by 5.85%. In the past year, price increased by 0.98%.
RNXT Key Statistics
- Market Cap
- 46.402M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.32
- Dividend Yield
- N/A
RNXT Stock Performance
RNXT Stock Chart
RNXT Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to RNXT. When comparing the yearly performance of all stocks, RNXT is a bad performer in the overall market: 63.23% of all stocks are doing better.
RNXT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RNXT. RNXT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
RNXT Earnings
On March 30, 2026 RNXT reported an EPS of -0.08 and a revenue of 238.00K. The company beat EPS expectations (1.96% surprise) and missed revenue expectations (-44.41% surprise).
RNXT Forecast & Estimates
10 analysts have analysed RNXT and the average price target is 8.16 USD. This implies a price increase of 692.23% is expected in the next year compared to the current price of 1.03.
For the next year, analysts expect an EPS growth of 13.14% and a revenue growth 210.14% for RNXT
RNXT Groups
Sector & Classification
RNXT Financial Highlights
Over the last trailing twelve months RNXT reported a non-GAAP Earnings per Share(EPS) of -0.32. The EPS increased by 20% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -137.96% | ||
| ROE | -205.98% | ||
| Debt/Equity | 0 |
RNXT Ownership
RNXT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.18 | 371.899B | ||
| AMGN | AMGEN INC | 15.37 | 189.187B | ||
| GILD | GILEAD SCIENCES INC | 15.89 | 174.329B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.81 | 113.007B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.12 | 79.873B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.72 | 45.013B | ||
| INSM | INSMED INC | N/A | 33.111B | ||
| NTRA | NATERA INC | N/A | 30.421B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.133B | ||
| BIIB | BIOGEN INC | 11.1 | 26.264B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.79 | 25.357B | ||
| MRNA | MODERNA INC | N/A | 20.956B | ||
| INCY | INCYTE CORP | 12.62 | 19.441B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RNXT
Company Profile
RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a therapy platform to deliver chemotherapy. The company is headquartered in Mountain View, California and currently employs 10 full-time employees. The company went IPO on 2021-08-17. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
Company Info
IPO: 2021-08-17
RENOVORX INC
2570 W. El Camino Real, Ste. 320,
Mountain View CALIFORNIA US
CEO: Shaun R. Bagai
Employees: 10
Phone: 14088002649
RENOVORX INC / RNXT FAQ
What does RENOVORX INC do?
RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a therapy platform to deliver chemotherapy. The company is headquartered in Mountain View, California and currently employs 10 full-time employees. The company went IPO on 2021-08-17. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
Can you provide the latest stock price for RENOVORX INC?
The current stock price of RNXT is 1.03 USD. The price increased by 0.98% in the last trading session.
Does RENOVORX INC pay dividends?
RNXT does not pay a dividend.
What is the ChartMill rating of RENOVORX INC stock?
RNXT has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of RENOVORX INC (RNXT)?
RENOVORX INC (RNXT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.32).
What is RENOVORX INC worth?
RENOVORX INC (RNXT) has a market capitalization of 46.40M USD. This makes RNXT a Nano Cap stock.
What is the outstanding short interest for RENOVORX INC?
The outstanding short interest for RENOVORX INC (RNXT) is 1.44% of its float.